# Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

> **NCT01166542** · PHASE3 · COMPLETED · sponsor: **Oncolytics Biotech** · enrollment: 167 (actual)

## Conditions studied

- Carcinoma, Squamous Cell of the Head and Neck

## Interventions

- **BIOLOGICAL:** REOLYSIN
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01166542
- **Lead sponsor:** Oncolytics Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-04
- **Final completion:** 2014-05
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2014-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01166542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01166542, "Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01166542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*